PL2863918T3 - Kryształy soli inhibitora pde1 - Google Patents

Kryształy soli inhibitora pde1

Info

Publication number: PL2863918T3
Authority: PL; Poland
Prior art keywords: salt crystals; pde1 inhibitor; pde1; inhibitor; crystals
Prior art date: 2012-06-21

Application number

PL13806448T

Other languages

English (en)

Inventor

Peng Li

Lawrence P. Wennogle

Robert Davis

Graham Buckton

Mark Hooper

Original Assignee

Intra-Cellular Therapies, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-21

Filing date

2013-06-21

Publication date

2020-05-18

2013-06-21 Application filed by Intra-Cellular Therapies, Inc. filed Critical Intra-Cellular Therapies, Inc.

2020-05-18 Publication of PL2863918T3 publication Critical patent/PL2863918T3/pl

Links

229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
239000013078 crystal Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL13806448T 2012-06-21 2013-06-21 Kryształy soli inhibitora pde1 PL2863918T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261662355P	2012-06-21	2012-06-21
PCT/US2013/047123 WO2013192556A2 (en)	2012-06-21	2013-06-21	Salt crystals
EP13806448.0A EP2863918B1 (en)	2012-06-21	2013-06-21	Salt crystals of a pde1 inhibitor

Publications (1)

Publication Number	Publication Date
PL2863918T3 true PL2863918T3 (pl)	2020-05-18

Family

ID=49769726

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL13806448T PL2863918T3 (pl)	2012-06-21	2013-06-21	Kryształy soli inhibitora pde1

Country Status (18)

Country	Link
US (1)	US9469647B2 (pl)
EP (2)	EP2863918B1 (pl)
JP (3)	JP6506687B2 (pl)
KR (1)	KR102175024B1 (pl)
CN (2)	CN104602695B (pl)
AR (2)	AR091507A1 (pl)
AU (1)	AU2013278081B2 (pl)
BR (2)	BR122021026665B1 (pl)
CA (1)	CA2876001C (pl)
DK (1)	DK2863918T3 (pl)
ES (1)	ES2769523T3 (pl)
IL (2)	IL236069B (pl)
MX (1)	MX352831B (pl)
PL (1)	PL2863918T3 (pl)
RU (1)	RU2652116C2 (pl)
TW (1)	TWI652271B (pl)
UY (1)	UY34870A (pl)
WO (1)	WO2013192556A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006255028B2 (en)	2005-06-06	2012-04-19	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008070095A1 (en)	2006-12-05	2008-06-12	Intra-Cellular Therapies, Inc.	Novel uses
KR20120012831A (ko)	2007-12-06	2012-02-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
WO2010098839A1 (en)	2009-02-25	2010-09-02	Intra-Cellular Therapies, Inc.	Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja)	2009-05-13	2012-11-01	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
EP2576551A4 (en)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
AR091507A1 (es) *	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US9801882B2 (en)	2013-02-17	2017-10-31	Intra-Cellular Therapies, Inc.	Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968338B1 (en)	2013-03-15	2019-01-09	Intra-Cellular Therapies, Inc.	Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
KR102240326B1 (ko)	2013-03-15	2021-04-13	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
US9630971B2 (en) *	2013-06-21	2017-04-25	Intra-Cellular Therapies, Inc.	Free base crystals
JP6696904B2 (ja) *	2014-01-08	2020-05-20	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	製剤および医薬組成物
EP3157926B1 (en) *	2014-06-20	2019-05-15	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en)	2014-08-07	2018-11-20	Intra-Cellular Therapies, Inc.	Organic compounds
CA2961212C (en)	2014-09-17	2024-02-06	Intra-Cellular Therapies, Inc.	Compounds and methods
HK1244427A1 (zh)	2014-12-06	2018-08-10	Intra-Cellular Therapies, Inc.	有机化合物
CA2969594A1 (en)	2014-12-06	2016-06-09	Intra-Cellular Therapies, Inc.	Pde2 inhibiting organic compounds
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
JP7134168B6 (ja)	2016-09-12	2024-02-02	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
MX2020012628A (es)	2018-05-25	2021-01-29	Intra Cellular Therapies Inc	Compuestos organicos.
ES3001119T3 (es)	2019-03-28	2025-03-04	Amplia Therapeutics Ltd	Una sal y forma cristalina de un inhibidor de FAK
WO2020210614A1 (en)	2019-04-12	2020-10-15	Intra-Cellular Therapies, Inc.	Organic compounds
EP4413980A3 (en)	2019-09-03	2024-10-30	Intra-Cellular Therapies, Inc.	Novel compounds
US12435093B2 (en)	2020-05-06	2025-10-07	Intra-Cellular Therapies, Inc.	Free base crystals
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease
EP4469052A4 (en) *	2022-01-27	2026-02-11	Intra Cellular Therapies Inc	NEW COMPOSITIONS
EP4472638A4 (en) *	2022-01-31	2026-03-11	Intra Cellular Therapies Inc	SALT CRYSTALS

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9412571D0 (en)	1994-06-22	1994-08-10	Celltech Ltd	Chemical compounds
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
PL215006B1 (pl)	2002-02-08	2013-10-31	Ono Pharmaceutical Co	Krystaliczna postac pochodnej piperydyny oraz jej zastosowanie
EP1613747A1 (en)	2003-03-31	2006-01-11	Pfizer Products Inc.	Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
JP2007504230A (ja) *	2003-09-02	2007-03-01	メルク　エンド　カムパニー　インコーポレーテッド	ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
JP4996467B2 (ja) *	2004-09-27	2012-08-08	アカディアファーマシューティカルズインコーポレイテッド	Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
AU2006255028B2 (en)	2005-06-06	2012-04-19	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008063505A1 (en)	2006-11-13	2008-05-29	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008070095A1 (en)	2006-12-05	2008-06-12	Intra-Cellular Therapies, Inc.	Novel uses
KR20120012831A (ko) *	2007-12-06	2012-02-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
US20120070443A1 (en)	2008-12-02	2012-03-22	University Of Utah Research Foundation	Pde1 as a target therapeutic in heart disease
KR20110103949A (ko) *	2008-12-06	2011-09-21	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
MA32942B1 (fr) *	2008-12-06	2012-01-02	Intra Cellular Therapies Inc	Composes organiques
JP5778582B2 (ja)	2008-12-06	2015-09-16	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
WO2010098839A1 (en)	2009-02-25	2010-09-02	Intra-Cellular Therapies, Inc.	Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja)	2009-05-13	2012-11-01	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
WO2011043816A1 (en)	2009-10-08	2011-04-14	Intra-Cellular Therapies, Inc.	Phosphodiesterase 1-targeting tracers and methods
EP2576551A4 (en)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
JP6051210B2 (ja)	2011-06-10	2016-12-27	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
AR091507A1 (es) *	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US9630971B2 (en) *	2013-06-21	2017-04-25	Intra-Cellular Therapies, Inc.	Free base crystals

2013
- 2013-06-19 AR ARP130102175 patent/AR091507A1/es not_active Application Discontinuation
- 2013-06-21 BR BR122021026665-4A patent/BR122021026665B1/pt active IP Right Grant
- 2013-06-21 TW TW102122116A patent/TWI652271B/zh active
- 2013-06-21 CN CN201380032536.5A patent/CN104602695B/zh active Active
- 2013-06-21 AU AU2013278081A patent/AU2013278081B2/en active Active
- 2013-06-21 EP EP13806448.0A patent/EP2863918B1/en active Active
- 2013-06-21 JP JP2015518617A patent/JP6506687B2/ja active Active
- 2013-06-21 PL PL13806448T patent/PL2863918T3/pl unknown
- 2013-06-21 WO PCT/US2013/047123 patent/WO2013192556A2/en not_active Ceased
- 2013-06-21 MX MX2014015904A patent/MX352831B/es active IP Right Grant
- 2013-06-21 ES ES13806448T patent/ES2769523T3/es active Active
- 2013-06-21 RU RU2015101647A patent/RU2652116C2/ru active
- 2013-06-21 EP EP19219516.2A patent/EP3733675A1/en active Pending
- 2013-06-21 UY UY0001034870A patent/UY34870A/es not_active Application Discontinuation
- 2013-06-21 CN CN201710655577.XA patent/CN107602572A/zh active Pending
- 2013-06-21 DK DK13806448.0T patent/DK2863918T3/da active
- 2013-06-21 BR BR112014032338-0A patent/BR112014032338B1/pt active IP Right Grant
- 2013-06-21 KR KR1020147035045A patent/KR102175024B1/ko active Active
- 2013-06-21 CA CA2876001A patent/CA2876001C/en active Active
- 2013-06-21 US US14/409,988 patent/US9469647B2/en active Active
2014
- 2014-12-04 IL IL236069A patent/IL236069B/en active IP Right Grant
2018
- 2018-01-04 JP JP2018000202A patent/JP6853794B2/ja active Active
2019
- 2019-10-25 JP JP2019194580A patent/JP2020012003A/ja active Pending
2020
- 2020-03-12 IL IL273276A patent/IL273276A/en unknown
- 2020-10-29 AR ARP200102993A patent/AR120339A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR122021026665B1 (pt)	2022-12-06
JP6506687B2 (ja)	2019-04-24
AU2013278081B2 (en)	2017-06-29
HK1210017A1 (en)	2016-04-15
CA2876001C (en)	2021-06-08
ES2769523T3 (es)	2020-06-26
CN104602695A (zh)	2015-05-06
RU2652116C2 (ru)	2018-04-25
MX352831B (es)	2017-12-11
RU2015101647A (ru)	2016-08-10
DK2863918T3 (da)	2020-03-23
IL236069A0 (en)	2015-01-29
JP2020012003A (ja)	2020-01-23
IL273276A (en)	2020-04-30
JP6853794B2 (ja)	2021-03-31
TW201406763A (zh)	2014-02-16
AR091507A1 (es)	2015-02-11
CN107602572A (zh)	2018-01-19
US20150259353A1 (en)	2015-09-17
WO2013192556A3 (en)	2014-02-27
CA2876001A1 (en)	2013-12-27
AU2013278081A1 (en)	2015-01-22
EP2863918A2 (en)	2015-04-29
US9469647B2 (en)	2016-10-18
BR112014032338B1 (pt)	2022-04-26
BR112014032338A2 (pt)	2018-05-15
CN104602695B (zh)	2017-08-29
EP3733675A1 (en)	2020-11-04
AR120339A2 (es)	2022-02-09
WO2013192556A2 (en)	2013-12-27
JP2018065868A (ja)	2018-04-26
IL236069B (en)	2020-04-30
TWI652271B (zh)	2019-03-01
MX2014015904A (es)	2015-07-17
KR102175024B1 (ko)	2020-11-05
EP2863918B1 (en)	2019-12-25
KR20150023386A (ko)	2015-03-05
JP2015520243A (ja)	2015-07-16
EP2863918A4 (en)	2016-01-13
UY34870A (es)	2014-01-31

Publication	Publication Date	Title
PL2863918T3 (pl)	2020-05-18	Kryształy soli inhibitora pde1
PT2892889T (pt)	2018-01-09	Compostos inibidores
IL230940A0 (en)	2014-03-31	Noribogain salt ensolvates
EP2804479A4 (en)	2015-07-22	METALLOENZYME INHIBITOR COMPOUNDS
ZA201503238B (en)	2017-11-29	Crystalline forms of a factor xia inhibitor
EP2894981A4 (en)	2016-03-16	METALLO ENZYME INHIBITOR COMPOUNDS
PL2804858T3 (pl)	2020-06-29	Związki - inhibitory metaloenzymu
PT3293176T (pt)	2021-03-03	Forma cristalina de um inibidor de pde4
PH12013502483A1 (en)	2014-01-20	Use of a metal salt of 2-mercaptobenzothiazole
ZA201409327B (en)	2016-09-28	Solid forms of a pyrido-pyrimidinium inner salt
SMT202000173T1 (it)	2020-05-08	Cristalli di composti di 2-acilamminotiazolo
PL2888228T3 (pl)	2019-10-31	Inhibitory oddziaływania CD40-TRAF6
GB201211019D0 (en)	2012-08-01	Inhibitor compounds
SG10201405403QA (en)	2014-11-27	Novel salts of dpp-iv inhibitor
ZA201406238B (en)	2016-08-31	Crystalline form of a succinate salt
ZA201308872B (en)	2014-08-27	Use of a dinitromethane salt
ZA201205358B (en)	2013-05-29	Use of a salt of bistetrazolylamine
TWI561515B (en)	2016-12-11	Metalloenzyme inhibitor compounds
AP2013007101A0 (en)	2013-09-30	Novel salts of DPP-IV inhibitor
IL236946A0 (en)	2015-03-31	A10-type phosphodiesterase inhibitory compounds
HUP1200574A2 (en)	2013-06-28	Use of photochemically cleavable compounds
HUE050301T2 (hu)	2020-11-30	2-Acilamino-tiazol-vegyület kristályok